Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week

Fiuzat, M., Hamo, C. E., Butler, J., Abraham, W. T., DeFilippis, E. M., Fonarow, G. C., Lindenfeld, J., Mentz, R. J., Psotka, M. A., Solomon, S. D., Teerlink, J. R., Vaduganathan, M., Vardeny, O., McMurray, J. J. V., & O’Connor, C. M. (2022). Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. Journal of the American College of Cardiology, 79(5), 504–510. https://doi.org/10.1016/j.jacc.2021.11.033
Authors:
Mona Fiuzat
Carine E Hamo
Javed Butler
William T Abraham
Ersilia M DeFilippis
Gregg C Fonarow
Joann Lindenfeld
Robert J Mentz
Mitchell A Psotka
Scott D Solomon
John R Teerlink
Muthiah Vaduganathan
Orly Vardeny
John J V McMurray
Christopher M O'Connor
Affiliated Authors:
Ersilia M DeFilippis
Columbia Affiliation:
Subjects:
Cardiovascular Agents (MeSH)
Clinical Trials as Topic (MeSH)
Heart Failure (MeSH)
Periodicals as Topic (MeSH)
Stroke Volume (MeSH)
Author Keywords:
fda
hfref
clinical trials
device therapy
drug therapy
guideline directed medical therapy
heart failure
medical therapy
medication
elink
Publication Type:
Article
Unique ID:
10.1016/j.jacc.2021.11.033
PMID:
35115106
DOI:
10.1016/j.jacc.2021.11.033
Journal:
Journal of the American College of Cardiology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: